SLC26A9 promotes the initiation and progression of breast cancer by activating the PI3K/AKT signaling pathway

被引:0
作者
Ma, Zhiyuan [1 ,2 ,3 ]
Wang, Hu [1 ,2 ]
Zhou, Zhengxing [1 ,2 ]
Lu, Chengli [1 ,2 ]
Zhang, Minglin [3 ]
Mu, Renmin [1 ,2 ]
Zhang, Chengmin [1 ,2 ]
Yi, Zhiqiang [3 ]
Deng, Zilin [3 ]
Zhao, Yingying [3 ]
Zhu, Jiaxing [3 ]
Wen, Guorong [3 ]
Jin, Hai [3 ]
An, Jiaxing [3 ]
Tuo, Biguang [3 ]
Yuan, Peng [4 ]
Liu, Xuemei [3 ]
Li, Taolang [1 ,2 ]
机构
[1] Zunyi Med Univ, Affiliated Hosp, Dept Gen Surg, Zunyi, Peoples R China
[2] Zunyi Med Univ, Affiliated Hosp, Dept Thyroid & Breast Surg, Zunyi, Peoples R China
[3] Zunyi Med Univ, Affiliated Hosp, Digest Dis Hosp, Dept Gastroenterol, Zunyi, Peoples R China
[4] China Acad Med Sci, Affiliated Tumor Hosp, Beijing, Peoples R China
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 2025年 / 1872卷 / 03期
基金
中国国家自然科学基金;
关键词
PI3K/AKT; Proliferation; Migration; Invasion; Breast cancer; EXPRESSION PATTERNS; GENE FAMILY; CELLS; TUMORIGENESIS;
D O I
10.1016/j.bbamcr.2025.119912
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SLC26A9 is a member of the Slc26a family of multifunctional anion transporters that function as Cl channels in the stomach. We reported for the first time that SLC26A9 is involved in gastric tumorigenesis. However, the role of SLC26A9 in breast cancer has not yet been investigated. We first demonstrated that the upregulation of SLC26A9 is associated with the clinicopathological progression and poor prognosis of patients with breast cancer and is positively correlated with HER2 amplification. SLC26A9 alters the proliferation, migration, and invasion potential of breast cancer cells by regulating the PI3K/AKT signaling pathway. SLC26A9 acts as an oncogene in the development of breast cancer. These findings provide valuable insights for the development of future diagnostic and therapeutic strategies for BC.
引用
收藏
页数:11
相关论文
共 32 条
[31]   SLC26A9 promotes colorectal tumorigenesis by modulating Wnt/β-catenin signaling [J].
Zhang, Minglin ;
Ma, Zhiyuan ;
Yi, Zhiqiang ;
Wang, Hu ;
Zhu, Jiaxing ;
Wen, Guorong ;
Jin, Hai ;
An, Jiaxing ;
Deng, Zilin ;
Tuo, Biguang ;
Li, Taolang ;
Liu, Xuemei .
CELL DEATH DISCOVERY, 2024, 10 (01)
[32]   Pathophysiological role of ion channels and transporters in HER2-positive breast cancer [J].
Zhou, Zhengxing ;
Zhang, Chengmin ;
Ma, Zhiyuan ;
Wang, Hu ;
Tuo, Biguang ;
Cheng, Xiaoming ;
Liu, Xuemei ;
Li, Taolang .
CANCER GENE THERAPY, 2022, 29 (8-9) :1097-1104